• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Medical Officer Keenan Greg sold $68,350 worth of shares (8,305 units at $8.23), decreasing direct ownership by 5% to 153,484 units (SEC Form 4)

    3/7/25 5:25:05 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AUPH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Keenan Greg

    (Last) (First) (Middle)
    #140, 14315 - 118 AVENUE

    (Street)
    EDMONTON A0 T5L 4S6

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Aurinia Pharmaceuticals Inc. [ AUPH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    03/07/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/07/2025 S 8,305(1) D $8.23(2) 153,484 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units related to the March 6, 2023 grant.
    2. The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.20 to $8.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
    Remarks:
    /s/ Greg Keenan, M.D. 03/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AUPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AUPH

    DatePrice TargetRatingAnalyst
    11/4/2022Outperform → Perform
    Oppenheimer
    5/5/2022$34.00 → $25.00Overweight
    Cantor Fitzgerald
    3/8/2022$30.00 → $22.00Outperform
    SVB Leerink
    3/1/2022$31.00 → $27.00Outperform
    RBC Capital
    2/23/2022$34.00 → $31.00Outperform
    RBC Capital
    12/10/2021$33.00 → $31.00Perform → Outperform
    Oppenheimer
    11/4/2021$32.00 → $33.00Perform
    Oppenheimer
    11/4/2021$35.00 → $40.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AUPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

      LUPKYNIS Data Presented at LUPUS 2025, the 16th International Congress on SLE, May 21-24 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), today announced that a post-hoc analysis of the 52-week, Phase 3 AURORA 1 study showed that lupus nephritis (LN) patients who received triple immunosuppressive therapy with LUPKYNIS® (voclosporin), mycophenolate mofetil (MMF), and low-dose glucocorticoids achieved lower proteinuria targets at substantially higher rates compared to patients in the control group who received mycophenolate mofetil (MMF) and low-dose glucocorticoids alone. The analysis assessed the achievement of urine protein creatine ratio (UPCR) targets of ≤0.4 g/g, ≤

      5/22/25 6:00:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Results Total Revenue: For the three months ended March 31, 2025, total revenue was $62.5 million, up 24% from $50.3 million in the same period of 2024. Net Product Sales: For the three months ended March 31, 2025, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $60.0 million, up 25% from $48.1 million in the same period of 2024. License, Collaboration and Royalty Revenue: For the three months ended March 31, 2025, license, collaboration and royalty

      5/12/25 6:00:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release first quarter 2025 financial and operational results before markets open on May 12, 2025. Aurinia's management team will host a conference call and webcast at 8:30 AM ET that day to review these results and provide a general business update. The link to the audio webcast is available here. To join the conference call, please dial 877-407-9170 / +1 201-493-6756. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia Pharmaceuticals is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medi

      5/5/25 6:00:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AUPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tang Kevin bought $12,713,126 worth of shares (1,600,000 units at $7.95) (SEC Form 4)

      4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

      3/4/25 5:03:02 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Tang Kevin bought $10,822,000 worth of shares (1,200,000 units at $9.02) (SEC Form 4)

      4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

      12/9/24 4:52:50 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AUPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for LUPKYNIS

      Submission status for AURINIA PHARMACEUTICALS, INC.'s drug LUPKYNIS (ORIG-1) with active ingredient VOCLOSPORIN has changed to 'Approval' on 01/22/2021. Application Category: NDA, Application Number: 213716, Application Classification: Type 1 - New Molecular Entity

      1/25/21 11:31:10 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AUPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aurinia Pharma downgraded by Oppenheimer

      Oppenheimer downgraded Aurinia Pharma from Outperform to Perform

      11/4/22 7:15:31 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on Aurinia Pharma with a new price target

      Cantor Fitzgerald resumed coverage of Aurinia Pharma with a rating of Overweight and set a new price target of $25.00 from $34.00 previously

      5/5/22 9:08:41 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Aurinia Pharmaceuticals with a new price target

      SVB Leerink reiterated coverage of Aurinia Pharmaceuticals with a rating of Outperform and set a new price target of $22.00 from $30.00 previously

      3/8/22 4:46:01 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AUPH
    SEC Filings

    See more
    • SEC Form S-8 filed by Aurinia Pharmaceuticals Inc

      S-8 - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)

      5/16/25 5:01:56 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurinia Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)

      5/15/25 4:06:13 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Aurinia Pharmaceuticals Inc

      10-Q - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)

      5/12/25 6:05:39 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care